Attività
Vendite per attività
USD in Milioni | 2021 | Peso | 2022 | Peso | Delta |
---|---|---|---|---|---|
Immuno-oncology Therapeutics
100,0
%
| 0 | 100,0 % | 29 | 100,0 % | -6.068,12% |
Vendite per regione
USD in Milioni | 2021 | Peso | 2022 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 0 | 100,0 % | 29 | 100,0 % | -6.068,12% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Paul Kang
CEO | Chief Executive Officer | 63 | 24/02/23 |
Ji-Young Hwang
DFI | Director of Finance/CFO | 47 | 01/12/22 |
Investor Relations Contact | 47 | - | |
Joshua Miller
AUD | Comptroller/Controller/Auditor | 48 | 01/04/22 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Ji-Young Hwang
DFI | Director of Finance/CFO | 47 | 01/12/22 |
Paul Kang
CEO | Chief Executive Officer | 63 | 24/02/23 |
Hyuk Joon Ko
BRD | Director/Board Member | - | 23/08/23 |
Dongho Lee
BRD | Director/Board Member | - | 21/08/23 |
Hojoon Lee
BRD | Director/Board Member | - | 23/08/23 |
Minhee Eom
BRD | Director/Board Member | - | 26/09/23 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 8 648 307 | 4 753 248 ( 54,96 %) | 0 | 54,96 % |
Coordinate società
Settore
Variaz. 1 gen. | Capi. | |
---|---|---|
+5,33% | 111 Mrd | |
+12,11% | 106 Mrd | |
-12,56% | 22,24 Mrd | |
-3,70% | 21,25 Mrd | |
-6,03% | 18,97 Mrd | |
-35,21% | 18,52 Mrd | |
-10,86% | 16,81 Mrd | |
+5,10% | 13,94 Mrd | |
+37,57% | 12,54 Mrd |